Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Adds Access to the Bucharest Stock Exchange, Offering Access to One of Europe's Strongest-Performing Markets of 202513.8.2026 10:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced access to the Bucharest Stock Exchange (BVB). This expansion offers access to one of Europe’s strongest-performing emerging markets of 2025, expanding diversification opportunities for IBKR clients alongside over 170 other global exchanges on a single, advanced platform. Romania was elevated to MSCI’s Advanced Frontier Market status while the BET index reached record highs in 2025 and continued its growth through the first half of 2026. With this integration, IBKR clients can access Romanian equities through the same platform they use for markets worldwide, making it easier to incorporate Romanian listed companies into their global investment strategies. “Adding the Bucharest Stock Exchange expands the choices available to our clients and reinforces our commitment to providing the broadest possible access to global markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “Romania is one o
Lenovo Group: Q1 Financial Results 2026/2713.8.2026 07:16:00 EEST | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported first quarter results for fiscal year 2026/27, marking the highest quarterly revenue growth in the past five years and the strongest quarter in the Group’s history. During the quarter, overall Group revenue reached an all-time quarterly high of US$26.9 billion, up 43% year-on-year, with all business groups delivering record first-fiscal-quarter revenue and operating profit. Adjusted net income[1]was up 176% year-on-year to US$1.1 billion, surpassing the US$1 billion milestone for the first time ever, with adjusted net margin improvements of almost two percentage points year-on-year supported by higher revenue scale and continued efficiency gains. AI-related revenue[2] grew 60% year-on-year to US$9.3 billion, accounting for 35% of total Group revenue in Q1. The Group continues to invest in innovation with R&D expenses up 30% year-on-year. The first quarter results demonstrate the G
Suzano Reports Adjusted EBITDA of R$4.7 Billion in the Second Quarter of 202613.8.2026 02:27:00 EEST | Press release
Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2026 (2Q26), reporting higher prices, stronger volumes and improvements in Adjusted EBITDA and operating cash generation compared to the previous quarter. The quarterly results reflect the competitiveness and resilience of Suzano’s operations in a quarter marked by foreign exchange headwinds and pressure on input costs driven by higher oil prices affecting the industry as a whole. Suzano sold 3.3 million tonnes of pulp and paper combined in 2Q26, comprising 2.9 million tonnes of pulp and 406 thousand tonnes of paper across the packaging, printing and writing, specialty and tissue segments. Net revenue totalled R$11.6 billion and adjusted EBITDA reached R$4.7 billion, both above the levels recorded in the previous quarter. Operating cash generation reached R$2.9 billion, while net income totalled R$1.8 billion in 2Q26. Despite ongoing cost pressures, the cash cost of pulp production (excluding dow
Moody’s Corporation Elects Keith Demmings to Board of Directors12.8.2026 23:15:00 EEST | Press release
Moody’s Corporation (NYSE:MCO) today announced that Keith Demmings has been elected to the Company’s Board of Directors, effective November 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812902420/en/ Mr. Demmings, 54, currently serves as President and Chief Executive Officer of Assurant, Inc., a publicly traded company that safeguards and services connected devices, homes, automobiles, and commercial equipment in partnership with the world’s leading brands, a position he has held since January 2022. He has also served on Assurant’s Board of Directors since that time. Prior to his appointment as Chief Executive Officer, Mr. Demmings served as President of Assurant from 2021 to 2022, overseeing all operating segments, including Global Lifestyle and Global Housing. Earlier, he served as Executive Vice President and President, Global Lifestyle from 2016 to 2021, Executive Vice President and President, Global Markets
Lattice to Deliver Keynote at 2026 OCP Global Summit12.8.2026 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that Lattice will deliver a keynote at the 2026 OCP Global Summit. Ford Tamer, President and CEO of Lattice Semiconductor, will take the stage with Sanjoy Maity, Senior Vice President, AMI Business Unit Leader, Lattice Semiconductor. Together, they will discuss the growing need for a common management and control model for AI and compute infrastructure, and how the OCP Community can work together to bring this vision to life with existing open technologies. The keynote will take place on Tuesday, Oct. 13, 2026, at 10 a.m. PT at the San Jose Convention Center (SJCC), South Hall, San Jose, California. The OCP Summit is the premier event uniting the most forward-thinking minds in open IT Ecosystem development. The Summit presents a unique platform for the OCP community from around the globe to share their insights, foster partnerships, and showcase cutting-edge advancements in op
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom